Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TMhuCART19 IL18 - Kite Pharma

Next Previous
X
Search
Drug Profile

TMhuCART19 IL18 - Kite Pharma

Alternative Names: Anti-CD19 antigen/IL-18 expressing autologous CAR-T expressing IL-18 cell therapy; huCART19-IL18 cells; TmCD19-IL18 CAR T cells; TMhuCART19-IL18

Latest Information Update: 30 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kite Pharma
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma

Most Recent Events

  • 09 Nov 2023 Phase-I clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (IV) (NCT05989204)
  • 14 Aug 2023 University of Pennsylvania in collaboration with Kite pharma plans a phase I trial for Non Hodgkin Lymphoma (Second-line therapy or greater) in October 2023 (IV, Infusion) (NCT05989204)
  • 14 Aug 2023 Preclinical trials in Non-Hodgkin's lymphoma in USA (IV) prior to August 2023 (NCT05989204)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top